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ABSTRACT


Glioblastoma multiforme (GBM) is the most common primary brain tumor in
humans and is characterized as being highly aggressive and invasive, with the ability to
locally invade different areas of the central nervous system (CNS). GBM local invasion
undergoes an epithelial to mesenchmal like (EMT) process characterized by the loss of
cell-cell adhesion and increased cell mobility. The EMT-like switch in GBM is triggered
by a single transcription factor, Twist1, and is characterized by the loss of cell clustering,
re-organization of the basement membrane, and increased cell migration. GBM invasion
depends on the remodeling of the extracellular matrix (ECM) microenvironment, which
is induced in part by activated matrix metalloproteinases (MMPs). MMPs have
proteolytic activity, acting in the breakdown of the basement membrane (BM), and
facilitating cell proliferation, adhesion, migration and angiogenesis. The progression of
GBM tumor malignancy is a multistep process that involves cell-cell and cell-ECM
adhesion, invasion and migration. In this study, we examined the ability of the neural
ECM proteins vitronectin, fibronectin, laminin and collagen IV to trigger an EMT-like
response in GBM. We found that, monolayer formation of GBM cells on purified ECM
proteins exhibited the mesenchymal phenotype, but this did not lead to the induction of
the transcription factor Twist1, a marker used to determine GBM invasion. On the
contrary, we found that GBM cells grown on collagen IV show heightened levels of Twist
without the EMT-like switch in morphologies. These findings suggest an important role
for collagen IV in the process of GBM local invasion.
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REVIEW OF LITERATURE
I. Glioblastoma Multiforme
Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in
adults, and is characterized as highly aggressive and invasive, with the ability to locally
invade different areas of the central nervous system (CNS). The invasive properties of
GBM make it the most lethal of all primary brain tumor types1. Unlike other cancers,
GBM does not commonly metastasize to other areas of the body due to the blood brain
barrier, but it does invade normal tissue within the brain. Primary CNS tumors known as
gliomas are all derived from a common progenitor, the glial cell. Glial cells can consist of
ependymal cells, oligodendrocytes, or astrocytes. These subtypes of glial cells give rise to
distinct tumor types, but all are referred to as gliomas (Fig.1).

Figure 1. Cellular classification of gliomas – The common glial cells of the central nervous system include
several cell types, giving rise to distinct tumor types, all of which are classified as gliomas. Within the
CNS, neurons act as signaling cells transmitting impulses to and from the CNS, while neuroglial cells act as
support cells to the neurons, providing nutrients and protection2.

GBM is classified as an astrocytoma because it is derived from astrocytes.
Astrocytomas are categorized into four grades, higher grades being more deadly than
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lower ones; Grade 1-pilocytic Astrocytoma, Grade 2-Low-Grade Astrocytoma, Grade 3anaplastic Astrocytoma and Grade 4-Glioblastoma (GBM)1. Gliomas have been found to
grow in the brain stem, optic nerve, spinal cord, and cerebellum1. Of all yearly cases of
brain cancer, GBM accounts for 40% of diagnoses3, with a median overall survival rate
of 14.6 months and a median progression-free survival rate of 6.9 months 4. Common
clinical therapies for GBM patients include surgery, radiation therapy (XRT),
chemotherapy, and drug targeted therapeutics. The highly infiltrating and invasive
phenotype of GBM within the brain means that complete surgical excision is difficult,
and despite multi-modality treatments, GBM frequently recurs and is hence largely
incurable at this time 4. GBM local invasion is a complex process that involves intricate
tumor-host interactions that still remain to be fully elucidated. Through research,
scientists aim to interpret these interactions between cancer cells and the adjacent normal
brain tissue in hopes of personalizing treatment options for patients, instead of today’s
broad approach to fighting GBM. The GBM invasive phenotype is characterized by the
loss of cell-cell adhesion, adhesion to the extracellular matrix (ECM), and degradation of
the basement membrane. This allows cancer stem cells (CSCs) to move outside the
tumor’s original microenvironment, invading along nearby vasculature and white matter
tracts 5.
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II. Cancer Stem Cells (CSCs)
Although, there has been large strides in medical therapies and surgical
techniques, the outcomes for many GBM patients remains dismal. To blame for this
dismal outcome is a small population of tumor cells known as cancer stem cells (CSCs).
CSCs are characterized by the ability to self-renew and differentiate into specialized cell
types that recapitulate the bulk of the tumor6. However, the mechanisms driving CSCs to
create this heterogenic cell population is under debate. It is thought that heterogeneity of
tumor cells can arise as a response to differences between the external environment and
the tumor or by random genetic and epigenetic changes that allow cells to inherit
functional and phenotypic changes6. Cancers that follow the cancer stem cell model
contain a diverse population of cells, some being tumorigenic while others are nontumorigenic. The non-tumorigenic cells comprise the majority of cells within the tumor
and are not linked to tumor progression, while the small fraction of tumorigenic cells
leads to tumor progression by having the ability to self-renew and recapitulate the other
non-tumorigenic cell types7 (Fig.2). According to Robert Weinberg the cancer stem cell
model does not necessarily involve a normal stem cell as the cell of origin within a
tumor. According to his theory, cells that don’t have cancer stem cell properties can
undergo de-differentiation to become cancer stem cells. He believes that non-CSCs
undergo epithelial to mesenchymal transition to induce their de-differentiation into cancer
stem cells8.
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Figure 2. Cancer stem cell model and clonal evolution – Heterogeneity within tumors can occur through a
variety of factors including clonal evolution and environmental factors. Depicted on the left is a diagram
showing clonal evolution where epigenetic changes undergo selection by tumors leading to more
aggressive tumors overtime. The middle diagram shows the cancer stem cell model yellow and green cells
have non-tumorigenic traits while red cells are tumorigenic and have the capability of reproducing the bulk
of the tumor. The depiction on the right shows that clonal evolution and the cancer stem cell model along
with environmental factors can all influence tumor growth7.



Although this concept is widely accepted, there is also evidence suggesting that
brain tumor derived stem cells (BTSC) originate from neural stem cells (NSC). Neural
stem cells drive neurogenesis within the brain giving rise to neurons, astrocytes and
oligodendrocytes8. NSCs are found in two germinal regions of the brain the
subventricular zone of the lateral ventricle and the dentate gyrus of the hippocampus 8.
Since BTSCs share similar characteristics to NSCs such as self-renewel, multipotency
and relative quiescence, it has been proposed that GBM might arise from oncogenic
transformation of NSCs and from changes within the local environment 8,9. The cell of
origin is debated with compelling evidence supporting both sides. Since neural stem cells
14


are highly regulated, it is questioned how these cells could comprise tumors that are not
found in proximity to NSC germinal centers of the brain. Further adding to the debate is
the presence or absence of specific stem cell markers, and how researchers go about
quantifying their abundance or absence. Regardless of these debates, the mechanistic
biology behind NSC differentiation should be clarified in order to better our
understanding of genetic targets of BTSC differentiation in hopes of finding novel
therapies.
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III. Epithelial to mesenchymal transition (EMT)
Background
Epithelial to mesenchymal transition (EMT) and its reversion, mesenchymal to
epithelial transition (MET), are highly regulated developmental programs that first occur
in embryonic progression but are, also known to be key processes during cancer
metastasis. EMT is a succession of events that ultimately allows polarized epithelial cells
to dissociate from surrounding tissue and undergo a series of biochemical changes to
assume the phenotype of mesenchymal cells5,7. EMT-MET provides the cellular plasticity
between two distinct states: an adherent state (epithelial) and a highly mobile and
infiltrative state (mesenchymal). Mesenchymal cells are long spindle shaped
,undifferentiated stem cells that originate from the mesoderm with the ability to later
differentiate into distinct tissue types or to induce the differentiation of other nearby
cells8. These cells are essential building blocks for embryogenesis with the ability to
create bone, cartilage and all necessary connective tissue components.8
In contrast, their differentiated epithelial cell counterparts do not show great
mobility and are organized into tight adherent sheets of polygonal shaped cells held
together by adherens junctions11. These cell junctions are particularly abundant in
epithelial tissues and consist of protein complexes that provide contact between
neighboring cells and the extracellular matrix. The major cell-cell adhesion protein, Ecadherin, holds the sheets of epithelial cells together and prevents them from dissociating
from their neighbors5,11.When a switch in these phenotypes is triggered, it allows
enhanced cell migration, invasiveness and resistance to apoptosis 5. The multistep process
of EMT is typically orchestrated through activated transcription factors such as Snail,
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Slug, Twist, and Zeb1/25,10,12. These transcription factors are expressed in differing
combinations in a variety of cancers and have been shown in vitro to play important roles
in EMT invasion programming12. The changes evoked by these transcription factors
include the loss of E-cadherin, and the associated cell-cell adhesion, change from the
polygonal shape of an epithelial cell to the more elongated fibroblastic morphology of the
mesenchymal cell, expression of matrix degrading enzymes, and increased resistance to
apoptosis (Fig. 3). These traits are all known to occur during the invasion-metastasis
cascade3–5.

Figure 3. The mechanism of EMT and its reversion process MET – The mechanism of
EMT is associated with loss of cell-cell adhesion and increased motility allowing cells to
intravasate nearby vasculature or tissue seeding new metastasis. Abbreviation: EMT,
epithelial to mesenchymal transition; MET, Mesenchymal to epithelial transition13.



In cancers of epithelial cell origin, EMT is characterized by the loss of E-cadherin
and the upregulation of N-cadherin. This cadherin switch is a hallmark of carcinomas,
and is a fundamental step in EMT, allowing cells to dissociate from the primary tumor
mass to seed new metastases 5,10,12,14. In contrast with epithelial tissue, E-cadherin is not
normally expressed in healthy brain tissue, neural cells, astrocytes or
oligodendrocytes15,16. Similarly, expression of E-cadherin within the diseased GBM brain
17


is also rare and appears to be different from carcinomas since its expression is linked to
tumorigenesis and poor prognosis15. In order to locally invade, GBM cells undergo a
different form of EMT that does not involve the canonical cadherin switch that is
typically seen in the majority of carcinomas16,17. Although the transcription factors Snail,
Slug, Twist, and Zeb1/2, have all been shown to coordinate EMT in carcinomas,
astrocytomas such as GBM use a single transcription factor, Twist, to initiate EMT 16,17.
Another notable difference is that in carcinoma EMT, mesenchymal cells intravasate
blood vessels to metastasize to distant sites of the body. In comparison, the infiltrative
path of GBM into the normal brain parenchyma occurs along the fibrous tracts lining the
outer walls of the brain vasculature and along myelinated white matter tracts18.

GBM Transcription Factor Twist
The basic helix-loop-helix (bHLH) protein, Twist, has elevated expression in high
grade gliomas as well as in developing embryonic brains, but is absent from glial cells of
normal brain tissue 17. Its expression is associated with reduced cell aggregation,
cytoskeleton re-organization, enhanced migration and adhesion to ECM protein
substrates16. These characteristics provide compelling evidence of Twist’s ability to
induce EMT in GBM. In vivo, Twist mRNA expression is directly correlated with tumor
grade, suggesting that Twist plays a possible role in the progression of GBM malignancy
and progression17. When Twist is over-expressed in GBM cell lines, this increased Twist
expression is associated with increased cell invasiveness and migration, two known
properties of high grade gliomas16,17.
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Conversely, knock-down of Twist results in the inhibition of glioma invasion 16.
Taken together these findings suggest a therapeutic significance for Twist inhibition and
its role in GBM progression should be further elucidated.

MMPs in basement membrane degradation
A major component of EMT is the triggering of CSCs to leave their original
microenvironments in order to seed metastases elsewhere in the body. Aiding in the
degradation of the basement membrane along with the normal extracellular matrix is a
family of hydrolytic enzymes known as matrix metalloproteinases (MMPs). MMP’s are
secreted by glioma cells as well as stromal cells of the tumor to aid in the remodeling of
the basement membrane (BM) during EMT19. These enzymes are organized into four
subclasses based on their substrate specificity2.There are 25 known MMP genes in
humans and many of these have implications in cancer2. MMP expression is induced by
cytokines, growth factors, tumor promoters, physical stress, oncogenic transformation,
and cell-matrix and cell-cell interaction2. They are regulated in a variety of ways
including gene expression, pro-enzyme activation, and inhibition through specific tissue
inhibitors (TIMPs)20. MMPs aid in the invasiveness of tumor cells by degrading ECM
proteins and releasing the growth factors embedded within the ECM to activate signal
transduction cascades that promote migration21. In the gelatinase sub-class of MMPs,
MMP-2 and MMP-9 predominate in glioblastoma and their mRNA and protein
expression levels are known to be higher in GBM patient biopsy tissue22,23. Both of these
MMPs are implicated in GBM proliferation and migration through the activation of
transforming growth factor- Į (TGF-Į) and ȕ (TGF- ȕ)2. In addition, the levels of these
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MMPs largely correlate with the histological grade of malignancy23. Likewise, MMP-9
and MMP-2 promote GBM invasion in vitro and in xenograft models18,21 and their
inhibition dramatically reduces the invasive phenotype26. Equally important, MMP2 gene
expression is thought to be upregulated by the transcription factor Twist in GBM16.
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IV. Extracellular matrix proteins
The normal brain parenchyma surrounding GBM tumors plays an essential role in
invasion progression. Normal brain function relies on the ability of ligands within the
ECM to bind cell surface receptors known as integrins. This binding activates biological
pathways that regulate the physical properties of the ECM and tissue function such as cell
proliferation, differentiation, adhesion and mobility27. During EMT progression, MMPs
disrupt this normal environment, causing changes in the interaction between ECM
ligands and their cell surface receptors. The disruption of the ECM enables ligands
embedded within the matrix to freely bind to cell surface receptors, enabling pathways
that were once regulated to go unchecked. Furthermore, glioma cells actively secrete
fibrous proteins that have greater protein cross-linking, remodeling the ECM from the
soft normal brain to a more rigid tumor- like ECM 28. The increased protein cross-linking
facilitates cell migration along with the binding of ligands to integrin receptors leading to
the progression of cancer through EMT 29.
The developing fetal brain shows characteristics similar to that of the GBM brain,
having elevated levels of fibrous ECM proteins. This is in contrast to the mature adult
brain, which shows significantly lower expression of the same ECM proteins30. The fetal
brain ECM expresses elevated levels of the fibrous proteins, fibronectin, laminin,
vitronectin and collagen31. The most abundant brain protein hyaluronan (HA), has also
been shown to be elevated in the matrices of gliomas, similar to what is seen for the
embryonic brain matrix32.
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Normal Brain ECM
The composition and organization of the ECM within the normal brain is
significantly different from the ECM outside of the CNS. The ECM outside of the CNS
is well defined in composition and organization, consisting mainly of collagens,
glycosaminoglycans (GAG) or proteoglycans (PG) that exhibit unique variations and
amounts of ECM molecules. This accounts for the great diversity amongst differing organ
systems. In contrast, the ECM within the CNS is not as well organized and has yet to be
fully defined. It was not until the late 1970s with the use of electron microscopy that the
ECM of the brain was investigated.
The high degree of variation amongst PGs , GAGs, and ECM proteins allows
them to vary in function, acting as cofactors and regulators of growth factors that
influence neural cell adhesion, neuron growth, ECM organization and tumor cell
invasion33 .The parenchyma surrounding the brain has been characterized as an
amorphous matrix consisting of hyaluronic acid (HA), collagen and fibrous proteins2,34.
Carbohydrates are also abundant in the brain parenchyma and may be bound to core
proteins to form proteoglycans (PG), or unbound as the GAG hyaluron (HA) 33.
Hyaluron, also known as hyaluronic acid (HA), is the most broadly distributed ECM
molecule and is found in both grey and white matter. Its role is to organize the structure
of the ECM by eliciting changes in matrix conformation, from extensive chains to
condensed rods, and coils35. HA also plays an important role in creating the water-rich
environment of the brain. Due to its highly anionic nature, it attracts cations, causing an
osmotic influx of water18. In addition, proteoglycans are present in the ECM of the brain
at high concentrations, being formed by the covalent attachment of one or more GAG
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side chains to a core protein. Due to variations in the types of side chains, lengths and
alternative splicing, GAGs exist in many different isoforms33. Fibrous proteins have been
detected throughout the brain, mostly residing in the basement membranes surrounding
the cerebral vasculature and perivascular space33,36. The fibrous proteins associated with
these blood vessels are type-IV and type-V-collagens, fibronectin, laminin, and heparansulfate proteoglycans2,36,37.

GBM Brain ECM
Malignant brain tumor fatality is caused by the invasiveness of glioma cells under
the influence of the newly synthesized cellular microenvironment. During the
progression of GBM malignancy, EMT triggers the invasive behavior of glioma cells,
signaling them to degrade the normal ECM and replace it with a rigid fibrous ECM.
Degradation of the ECM by MMPs allows for aberrant interactions between GBM cells
and the ECM, resulting in the dissemination of single tumor cells into the brain
parenchyma by traveling along myelinated white matter tracts and blood vessels33 . In
addition, glioma cells begin synthesizing and secreting new ECM molecules with greater
amounts of cross-linking, making them more rigid when compared to the normal brain28.
Rigidity directly coincides to glioma grade, with higher grades demonstrating
more rigidity than lower ones 31. As an example vitronectin (VN), a fibrous protein
detected in GBM, is reported to be undetectable within the normal brain and is
unassociated in glial cells, neuronal cells, or cerebral white matter36
VN expression is detectable in late stage GBM, but is absent in normal and early stage
GBM brains 34,35.
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Table 1: Differences in the ECM of normal brain tissue and GBM diseased brains
Molecules
Hyaluronic Acid (HA)
Proteoglycan (PG)
Fibrous Proteins
 Vitronectin
 Fibronectin
 Laminin
 Collagen IV
Matrix
metalloproteinases
(MMPs)

Abundance
Normal Brain
Glioma
Ĺ
Ĺ

ĹĹĹ
ĹĹĹ

Found in trace
amounts along
brain vasculature
and basement
membrane.
Vitronectin exists
at extremely low
levels.

ĹĹĹ
ĹĹĹ
ĹĹĹ
ĹĹĹ

Ĺ

ĹĹĹ

Function
HA: space filling molecule,
regulates cell proliferation,
adhesion and motility.
PG: HA binding proteins
Fibrous Proteins: structural
elements of connective tissue in
the basement membrane of blood
vessels of the normal brain and
gliomas; in high grade gliomas
they are also expressed and
secreted by glioma cells.
MMPs: Molecules that aid in the
breakdown of the basement
membrane during ECM
remodeling; MMP-2, MMP-9

Vitronectin is thought to be one of the major factors in human serum that
promotes the migration of glioma cells and the differentiation of cancer stem cells39.
When CSCs are cultured in VN-containing serum, they lose expression of stem cell
maintenance genes and have an induced cytokeratin profile that is typically seen in
mesenchymal conversion40. Vitronectin has been localized to the tumor-brain interface in
GBM, primarily displayed at the plasma membrane and in the cytoplasm of the primary
tumor41. Because of its localization to the tumor mass and not the vasculature, it has been
suggested that VN is tumor cell derived41.
Likewise, hyaluronan (HA) expression is elevated approximately four-fold in the
matrices of gliomas relative to normal ECM42. The protein fibronectin is similar in
biochemical structure to VN and is also expressed by GBM cells in vitro and along blood
vessel migratory tracts surrounding tumors in vivo2. Ulrich et al. revealed that GBM cells
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grown on fibronectin coated plates show an altered morphology and cytoskeletal
organization similar to that of the mesenchymal phenotype. They discovered that multiple
GBM cell lines show this altered morphology when plated on rigid substrates and that
plating on softer substrates results in decreased cell spreading, stress fibers and focal
adhesions. The protein laminin is detectable in and along blood vessels and is found to
associate with the foot processes of neurons in the basal lamina of the brain43.
Interestingly, laminin was found to take on multiple isoforms and these were associated
with different grades of gliomas44. Laminin along with collagen type IV are the major
components making up the basement membrane of the brain and are commonly
associated with the neural vasculature2,23,45.
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V. Cellular communication
Role of Integrins
EMT- induced GBM tumor cell invasion is influenced by a variety of growth
factors and extracellular matrix (ECM) signals within the brain microenvironment45.
Neuronal cells communicate with protein components within the ECM via a family of
transmembrane surface receptors known as integrins46. Integrins are comprised of Į and ȕ
subunits and their heterodimeric pairing confers specificity of binding to one or more
substrates. The five members of the Įv integrin subfamily Įvȕ1, Įvȕ3, Įvȕ5, Įvȕ6 and
Įvȕ8 are expressed in neural and vascular cells of the brain and bind to arginine-glycineaspartic acid (RGD) peptide motifs present in many shared ECM ligands47. In contrast
with other cell surface receptors integrins are able to communicate through “inside-out”
and “outside-in” signaling, signals from the cell’s interior travel out of the cell to the
external environment and signals from the external environment are transferable to a cells
interior48. Integrin signaling is important in many cellular processes such as adhesion,
migration, polarity, cell survival, apoptosis and proliferation49.

Integrin expression within GBM
Of all the integrins associated with GBM, none has been more documented than
Įvȕ3. The Įvȕ3 integrin is documented to colocalize with MMP2 at the leading edge of
invading tumor cells48 and within endothelial cells along newly formed vasculature41. The
integrins Įvȕ3 and Įvȕ5 have been implicated in tumor-induced angiogenesis within
gliomas were they up-regulate basic fibroblast growth factor (bFGF) along with tumor
necrosis factor (TNF- Į)48. A driver of Įvȕ3 signaling is the ECM ligand VN41.
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Expression of Įvȕ3 is associated with the increased expression of the ECM protein VN at
the leading edge of invasive glioma tumors41. Given these points, it is fair to suggest that
the interaction between the Įvȕ3 integrin and VN contributes to the invasive behavior of
GBM. If in fact it does, this could lead to better use of anti-glioma drugs like the RGD
inhibitor cilengitide, while giving researchers more insight into personalized treatment
options for patients.

Cilengitide in GBM therapy


Because integrin signaling leads to tumor cell migration, proliferation, and

invasion, integrin-inhibiting drugs have been a recent development in the fight against
GBM. Of these Įv integrin antagonists, the antitumor drug Cilengitide has made
headway in the reduction of GBM progression. Cilengitide is a cyclic RGD peptide
inhibitor for the Įvȕ3 and Įvȕ5 integrins and is currently being tested in a phase III
clinical trial50,51 . In glioblastoma the integrin Įvȕ3 has been found to localize with the
protein vitronectin and the matrix metalloproteinase MMP2 at the tumor brain interface41.
Early clinical trials of Cilengitide have demonstrated anti-tumor activity, increased
patient remission and even increased patient survival for a small populations of GBM
patients50. The early results from these phase trials show the efficiency of integrin
inhibition and it is now being determined if Cilengitide in conjunction with other agents
might enhance the effectiveness of these therapies50,51.Going forward, the future success
of developing therapeutic integrin inhibitors for GBM patients depends on the
understanding of integrin expression amongst differing cell types, in particular those in
neural microenvironments.
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MANUSCRIPT
I. Introduction
Glioblastoma multiforme (GBM) is the most common primary brain tumor in
humans1 and is characterized as being highly aggressive and invasive, with the ability to
locally invade different areas of the central nervous system (CNS). GBM tumors are
known to contain sub-populations of cells referred to as cancer stem cells (CSCs). CSCs
are important for producing the cells that compose the bulk of the tumor, initiating
secondary tumors through local invasion and contributing to the development of drug
resistance. CSCs display the innate characteristics of stem cells in their ability to selfrenew and recapitulate the multiple cell types that compose the bulk heterogeneous
tumor9,10,47 .
A key event in cancer metastasis is the, epithelial to mesenchymal transition
(EMT) a biological process characterized by the loss of cell-cell adhesion and increased
cell mobility similar to that occurring in embryonic developement5,10,12. Unlike the
metastasis of carcinomas, GBM does not undergo EMT via a canonical cadherin switch.
The mesenchymal conversion in GBM is induced by the transcription factor Twist, as
Twist expression correlates with less cell clustering, re-organization of the basement
membrane, and increased cell migration16,17. GBM invasion depends on the remodeling
of the extracellular matrix (ECM) microenvironment, which is induced in part by
activated matrix metalloproteinases (MMPs). MMP expression has been implicated in
several cancers and its overexpression correlates with progression of disease. MMPs have
proteolytic activity, acting in the breakdown of the basement membrane (BM), and
facilitating cell proliferation, adhesion, migration and angiogenesis22.
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The progression to tumor malignancy is a multistep process that involves cell-cell
and cell-ECM adhesion, invasion, migration, and angiogenesis. . It has been shown in
numerous studies that GBM tumor cells interact with the ligands laminin, fibronectin
collagen IV and vitronectin and respond by altering morphology, invasiveness,
proliferation, and enabling differentiation

23,31,36,38,40,41,51

. These fibrous ECM proteins

are elevated in high grade gliomas, thus providing a more rigid framework for cell
migration along white matter tracts and blood vessels the predominant highways for
GBM invasion. Although, it is widely believed that this cell-substrate interaction in GBM
is EMT-like, it has not been proven. In this study, we aim to address whether one or more
of these fibrous ECM proteins of the brain vasculature initiates EMT in gliomas through
the up regulation of Twist, triggering recruitment of MMPs to facilitate subsequent
invasion. We seek to elucidate this by assaying for the up regulation of the mesenchymal
marker Twist1in response to the various ECM proteins. By studying this step in EMT
transition we will be able to determine which of these specific ECM proteins initiates
tumor metastasis. We also hypothesize that if Twist is induced by one or more of these
substrates, then MMP-2 expression will increase with heightened Twist levels. By
assaying for MMP-2 expression, we will be able to provide more evidence proving that
an EMT-like switch is associated or initiated by the proteins of the brains ECM.
Furthermore, it is our belief that potential therapeutic advances in GBM should target this
EMT-MET switch to disable the invasive machinery of GBM. By targeting this switch we
could potentially increase life expectancy for these patients and help reduce the dismal
outcomes many GBM patients and their families face.
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II. Preliminary studies
Henry Ford Hospital (Ana DeCarvalo) has recently developed an in vitro cell
culturing system that mimics the EMT-MET process. We have adopted this in vitro cell
culture model in order to study the events of the EMT switch that occurs in GBM. When
HF2587 glioma cells are grown in serum free neurosphere media (NMGF) (Table 2), they
form groups of clusters or 3-dimensional spheres. The cells take on an epithelial-like
phenotype with cell-cell adherence and increased proliferation. Upon neurosphere
dissociation and transfer to media containing 10% fetal bovine serum (FBS, Table 3)
these same cells exhibit a mesenchymal morphology with focal adhesions, cell-substrate
interactions, increased migration and slower proliferation rates. Transferring cells from
serum-free neurosphere media to media containing 10% fetal bovine serum induces an
EMT-like switch that is reversible (mesenchymal to epithelial transition, MET) by
transferring cells out of serum-containing media into serum-free neurosphere media. The
plasticity between EMT and MET is implicated in cancer metastasis and our system
accurately models these switches.

Table 2: Formulation of neurosphere media with growth factors (NMGF)
Material :
Composition:
Concentration:
Dulbecco's Modified Eagle Medium
Nutrient Mixture F-12 (DMEM/F12)
media (Gibco 11330)

L-glutamine, D-glucose,
Sodium Pyruvate, HEPES

N-2 Supplement (Gibco 17502-048)

Insulin, human transferrin,
50mg/ml
progesterone, putrescine, selenite

Bovine serum albumin (BSA) (Sigma
A4919)
Gentamicin Reagent (Gibco 15750060)
Epidermal growth factor (EGF)
(Peprotech 100-15)
Fibroblast growth factor-B
(FGF)(Peprotech 100-18B)

Albumin

50mg/ml

Aminoglycoside antibiotic

25 µg/ml

Recombinant Human EGF

50µg/ml

Recombinant Human FGF-2 (1
of 23)

50µg/ml

30


Table 3: Formulation of media supplemented with 10 % fetal bovine serum (FBS)
Material:

Composition:

Concentration:

Dulbecco's Modified Eagle Medium
(DMEM) (Gibco 11995-065)
Fetal bovine serum (FBS)

Glucose, L-Glutamine, Sodium
Pyruvate
Blood serum from fetal calf

10%

In order to validate the EMT-MET cell culture system, our first experiment was to
look at morphological changes of HF2587 cells grown in FBS, NMGF, and NMGF
supplemented with the fibrous protein vitronectin. The glioblastoma cell line HF2587
was plated in two separate culture conditions, serum free and FBS. Cells grown in serum
free media supplemented with N2 (insulin), bovine serum albumin (BSA), epidermal
growth factor (EGF), basic fibroblast growth factor-2 (FGF2), maintained an epitheliallike phenotype with robust cell-to-cell adhesion and well- formed neurospheres. Under
these conditions HF2587 cells exhibit a high proliferation rate, strong intercellular
adhesion to form spherical clusters, and an epithelial like morphology. Cells grown in
media containing 10% FBS shifted to a fibroblast-like morphology with slower
proliferation and cell-substrate (Fig. 4.A) (ECM) adherence vs. cell-cell adhesion (Fig.
4.B). Most noticeably, the cells grown in FBS grew as a monolayer rather than in
spherical clusters. Our next step was to determine whether the protein vitronectin, a
major component in serum, induces the same switch in phenotype from spheres to a
monolayer with increased cell-substrate adherence. Cells cultured in serum-free media
supplemented with purified vitronectin alone underwent a morphological change similar
to that induced by serum (Fig. 4.C). This demonstrates that vitronectin, a major
component of serum, may play a key role in mesenchymal conversion in this GBM
model system and suggests a pivotal role for the extracellular matrix in GBM migration.
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Figure 4. In vitro HF2587 cell culturing system – HF2587 cultured cells showing differing morphologies.
A.) HF2587 cells are grown in serum containing media and form adherent monolayer. B.) HF2587 cells
grown in serum free NMGF media exhibit the epithelial phenotype. C.) HF2587 cells are grown in serum
free NMGF media supplemented with VN (3µg/µl). These cells were allowed to grow for 5 days at 37°C.

To confirm the accuracy of our EMT-MET cell culturing system at the
transcriptional level, we sought to detect gene expression of the mesenchymal marker
Twist1. HF2587 GBM cells were grown as neurospheres or as adherent cells for two
weeks and harvested. A portion of the adherent cells weren’t harvested and were allowed
to continue growing as adherent cells while the remainder underwent reversion by
placing them in serum-free media. After 2 weeks of reversion, RNA was extracted from
all the groups of the harvested cells and qPCR for TWIST1 expression was performed.
The results from the first harvest showed that the cells grown in serum had a 5 fold
induction of TWIST1, suggesting that a Twist-mediated mesenchymal conversion was
occurring (Fig. 5.A). The same qPCR of Twist1 in the cells reverted by removal of serum
was associated with the loss of the mesenchynal marker Twist1 (Fig. 5.B).
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Figure 5. Gene expression differences of Twist1 from neurospheres to adherent cells, and the reversion of
adherent cells back to neurospheres – TWIST gene expression levels for HF2587 cells maintain for 4 weeks
in FBS and NMGF. Bars are represented by minimum and maximum values. A.) Gene expression levels for
TWIST show that cells grown in serum containing media exhibit a 5 fold induction of TWIST compared to
cells grown in serum free media. This induction of TWIST has been shown to trigger EMT in GBM. B.) To
show the reversion of this process (MET) a portion of the cells grown in FBS from figure A were split into
two cultures FBS and NMGF. The cells maintained in FBS continued to express TWIST but the cells grown
in NMGF reverted back to the normal levels of TWIST seen in figure A.

The results from the qPCR data verify the accuracy of our in vitro EMT cell
culturing system. To support the qPCR data a Western blot for TWIST1 protein
expression (Fig. 6) was carried out for cells grown in serum and cells grown in
neurosphere media. The figure demonstrates that TWIST1 was expressed in HF2587 cells
grown in FBS but the level of TWIST was undetectable in neurospheres. T98G is a GBM
cell line that was used as a positive control for its high expression of TWIST1 even when
grown in neurosphere media.
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Figure 6. Protein analysis of Twist in adherent cells compared to neurospheres – TWIST1 (MW: 26)
protein expression via Western blotting. T98G (+ control) is a human glioma cell line that over expresses
TWIST and was grown in NMGF media. HF2587 cells where grown in both FBS and NMGF media, the
results support our qPCR data showing that TWIST expression is higher in cells grown in serum containing
media.

To access the invasive capabilities of our cell line, immunodeficient mice were
orthotopically injected with HF2587 cells. The cells were grown in NMGF neurosphere
media prior to being injected into the mouse cranium. After 7 weeks of growth, the mice
were sacrificed and the brain tissue stained for human MHC class1. As depicted in figure
7, the cells underwent an EMT-like phenomenon, spreading out from the original
injection site.


Figure 7.Invasive nature of HF2587 in mice given orthotopic injections – Human MHC class 1 stain
(red/pink) after 7 weeks of growth. The dark accumulation of stain is the injection site. This demonstrates
the highly invasive and aggressive nature of GBM. Work done by David Monsma and Dawna Dylewski,
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III. Methods
Materials
Purified human extracellular matrix proteins where purchased as follows: Human
vitronectin and fibronectin from Invitrogen (Grand Island, NY). Collagen IV and laminin
from Santa Cruz Biotechnology (Dallas, TX). qPCR Taqman probes for both MMP2 and
TWIST where purchased from Applied Biosystems (Grand Island, NY). ). The HF2587
cell line was kindly provided by Ana Decarvalo of Henry Ford Hospital (Detroit
Michigan).All experiments used HF2587 cells that were under passage 21.
Cell Culture
HF2587 cells were routinely grown as neurospheres at 37°C with 10% CO in
Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 with glucose (DMEM/F12,
Gibco 11330) supplemented with N2, EGF, FGF2, and BSA (table 1). The cells were
grown for a period of three weeks, undergoing nine passages prior to being seeded in
specific ECM- coated wells
ECM coating
Flat bottom 12-well plates (Corning) were coated overnight at 37°C with purified
ECM proteins suspended in PBS (VN, FN, LAM) or 0.05N HCl (collagen IV). Human
vitronectin, laminin, and collagen IV were coated at a concentration of 4.5ȝg/cm².
Fibronectin coated wells were found to mediate attachment at a higher concentration of
10ȝg/cm². After overnight incubation, wells were blocked with BSA (1% w/v in PBS) for
1 hour at room temperature.
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Wells coated with BSA (10% w/v in PBS) served as controls for nonspecific
adhesion. HF2587 cells were plated at a density of 6 x 10 cells/ ml in NMGF media.
Cell Harvesting
Media was aspirated from the wells and the adherent cells were washed with PBS.
Adherent cells were then collected after addition of 0.25% trypsin EDTA (Gibco 15050065) for 1 minute at 37°C. Trypsin was inactivated by addition of twice the volume of
FBS cell media. Cells were collected and washed once in PBS. The cell pellets were then
flash frozen on dry ice prior to being stored at -80°C. HF2587 cells grown in suspension
were collected, washed once in PBS and the cell pellets were flash frozen on dry ice prior
to being stored at -80°C.
RNA Isolation
RNA was isolated from HF2587 cells, using the protocols from the RNeasy mini
kit and QIAshedder from Qiagen (Maryland). Extracted RNA was quantitated using the
NanoDrop spectrophotometer and then stored at -80°C.
cDNA Synthesis
Complementary DNA was synthesized with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) following the manufacturer’s protocol.
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Quantitative RT-PCR & Analysis
Quantitative RT-PCR was done on an Applied Biosystems Step One using
Taqman© master mix and one of the following Taqman© assays (Applied Biosystems):
MMP2, Twist1. Three biological replicates and three technical replicates were used for
each target analyzed. All threshold cycle (Ct) values were normalized to the endogenous
control ubiquitin c (UBC) and relative quantification was calculated from the median Ct
value.
Protein extraction


Nuclear and cytoplasmic proteins where extracted from HF2587 cells, using

protocol from the Nuclear Extraction Kit from Millipore (2900). Extracted nuclear
proteins where then quantified using the BCA assay.
Western Analysis
Nuclear and cytoplasmic proteins were separated by SDS-PAGE gel
electrophoresis and transferred to PVDF for Western blotting. The PVDF membrane was
blocked in 5% milk in Tris-buffered saline-0.05% Tween 20 (TBST) for 1 hour. The
primary antibody mouse monoclonal IgG 1:250 (Santa Cruz – 81417) was added and
incubated overnight on a rocking platform at 4°C. Following overnight incubation, the
membrane was rinsed 3 times in TBST for 10 minutes each. An anti-mouse IgG-HRP
secondary (GE Healthcare- NA931V) was then applied 1:5000 in 5% milk TBST. The
proteins were detected with ECL prime (GE Healthcare-RPN2232), with exposure
complete after 90 seconds.
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IV. Results
The HF2587 GBM cell line was originally derived from a patient GBM tumor biopsy
sample. Our preliminary findings with the in vitro EMT culturing system indicated that
after a two week time point, cells grown in FBS media expressed 5-fold or greater
expression of the transcription factor Twist when compared to cells grown in non-serum
containing neurosphere media. When the plates were coated with vitronectin we saw a
similar change in phenotype from 3-D spheres to single cell as seen with FBS media.
Because of this we believed that a possible role of ECM proteins could be to initiate
metastasis through the formation of monolayers and the induction of Twist and MMP2.
Time-dependent effects of ECM proteins on monolayer formation
Based on our preliminary work we knew that HF2587 cells would grow as a
monolayer on VN coated plates even in the presence of serum-free media. To test if
other ECM proteins induced the same behavior we coated Corning 12-well plates with
either fibronectin, collagen IV, vitronectin, or laminin. Serum- containing media (FBS)
served as a positive control, while cells grown in neurosphere media acted as a negative
control. To test for non-specific adherance10 % (w/v) BSA coated plates where used,
since BSA is an inert protein with regard to cell adhesion. Pictures were taken at 4, 12,
24, 48 and 72 hours intervals respectively.
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Figure 8. Time lapse of HF2587 monolayer formation on ECM substrates – Ability of HF2587 cells to form monolayers upon interaction with specific proteins of the neural
ECM. HF2587 grew as monolayers on the proteins vitronectin, fibronectin, laminin and the positive control FBS. Collagen IV appeared to have no affect on HF2587
neurospheres since they retained their spherical phenotype

ECM protein effect on cellular adhesion
Four hours following cell seeding on various ECM substrates, monolayers or
adherence occurred in the presence of fibronectin, vitronectin, and laminin. In contrast
cells grown on collagen IV started to sphere and there was no apparent adherence.
By 24 hours it was clear that collagen IV had no effect on the ability of HF2587
cells to form monolayers, but it was interesting to note that sphere size in these cultures
was, notably larger than with NMGF or BSA. Cells grown on vitronectin,fibronectin and
laminin retained their adherence and focal adhesions were present, similar to what is seen
with FBS. It should be noted, however that the monolayer morphology amongst these
three substrates was different. The adherence to fibronectin was unusual in that there
seemed to be some cell-cell adherence amongst the cells in the monolayer. In contrast,
laminin was completely in single cell monolayer with no cell-cell adherence, and the cells
adhered to the plate in fibroblast-like shapes. Vitronectin adherence was morphologically
similar to what is seen with fetal bovine serum. These cells were not in fibroblast shape
but they retained single cell adherence.
At 72 hours the monolayers remained intact and collagen IV still caused HF2587
to sphere. The unexpected observance was that the cells grown on collagen were not
rapidly dividing but rather sticking to one another forming increasingly large spheres.
When compared to cells grown in NMGF or on BSA it was evident that cell division had
slowed down dramatically on collagen. This observation was further clarified at 7 days
with a cell count during, the 7-day harvest. The wells containing cells grown on collagen
IV had the lowest number of cells per well. The morphology of the adherent cells had
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not changed from 24-72 hours; fibronectin still showed adherent clumping, and cells
grown on vitronectin were morphologically similar to the cells grown in FBS. Cells
grown on laminin continued to adhere in fibroblast-like shape. What was most alarming
at this time point was that cells grown on laminin had reach 80-90% confluence and
needed passaging. Our previous data from our EMT-MET in vitro cell culturing system
had shown that when cells formed monolayers, the rate of cell proliferation slowed down,
similiar to the characteristics of EMT. Because these cells were dividing so fast, it was a
strong indication that this was not EMT- like. Throughout the remainder of the 2 week
period the above observances did not change and remained static, although due to human
error the 13 day cells grown on fibronectin did not survive.
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Figure 9. HF2587 cells at 4 hours following plating on specific ECM proteins – HF2587 cells at 4 hours following plating on specific ECM proteins. Cells on fibronectin, laminin and vitronectin maintain
single cell phenotype similar to the positive control (FBS). Collagen IV caused cells to revert back to their cell-cell adherence and formed spheres.

4 Hours
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Figure 10. HF2587 cells at 24 hours following plating on specific ECM proteins – HF2587 cells at 24 hours following plating on specific ECM proteins. Cells on fibronectin, laminin and
vitronectin maintain single cell phenotype similar to the positive control (FBS). But these 3 substrates had differing morphologies amongst the monolayers. Collagen IV continued to cause cells to maintain cellcell adherence and sphere size was greatly increased from that of cells grown in NMGF.

24 Hours

44



Figure 11. HF2587 cells at 72 hours following plating on specific ECM proteins – HF2587 cells did not vary in morphology adherent cells and spherical cells remainied the same as they were at 24 and 48
hours.

72 Hours

Ability of ECM proteins to upregulate Twist1
We believed neural ECM substrates would cause HF2587 to form monolayers,
and Twist1 expression would increase as a result of this, since this was true in our in vitro
culturing system. It is known that ECM proteins cause glioma cells to become more
migratory and invasive. To test whether this invasiveness is associated with the induction
of EMT we performed gene expression analysis on the transcription factor Twist1.
Twist1 has been found to initiate EMT in GBM, and is up-regulated in high grade
gliomas. However, real-time quantitative PCR (qPCR) revealed that mRNA expression of
Twist1 was minimally affected by the formation of monolayers on specific ECM
substrates. We found that over a 7 day period the ECM proteins fibronectin, vitronectin,
and laminin actually had a decrease in Twist expression when compared to cells grown as
neurospheres. These results strongly disagree with our hypothesis that monolayer
formation on ECM substrates triggers increased Twist expression. Also, contradicting our
hypothesis, cells grown on the sphere forming collagen IV revealed a relatively
insignificant 1.46 fold increase in Twist when compared to NMGF. Consistent with
previous findings FBS had a 2.33 fold increase from NMGF Twist expression (Fig. 12).
Twist expression is time dependent; this has been seen in our preliminary
experiments where Twist was shown to increase 40 fold in a 4 week period. When the
current experiment was extended to 13 days, FBS expression of Twist increased from
2.33 to 5.60 fold.Laminin and vitronectin continued to show insignificant changes in
Twist at day 13. Similarly, collagen continued to increase expression of Twist1 from
1.46-fold on day 7 to 3.74-fold by day 13.
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BSA coated plates were used as a control in our experiment for non-specific
binding. Once again data is unavailable for the fibronectin 13 day time points (Fig. 13).
Ability of ECM proteins to upregulate MMP2
MMP2 is also a mesenchymal marker of EMT, enabling glioma cells to travel
outside the original tumor environment to seed secondary tumors, and has been linked to
high grade gliomas. If there is a true EMT-MET switch in our in vitro cell culturing
system then MMP2 expression should increase with increased expression levels of the
transcription factor Twist1. The results from our 7 day harvest concluded that MMP2 is
up-regulated 2.54 times more in FBS containing media in comparison to NMGF. This
result supports our belief that our In vitro system does in fact mimic an EMT-MET
transition. The ECM proteins vitronectin, fibronectin and collagen IV had minimal
effects on gene expression of MMP2, and expression levels were in fact lower than in
control cells grown in NMGF. Laminin increased expression of the MMP gene about
1.44fold relative to the control cell population.
As with Twist1, increasing the growth time on the ECM substrates to 13 days
allowed continued increases in MMP2 expression across all samples, confirming this
gene up-regulation is a time-dependent event. Surprisingly vitronectin had the largest
increase in MMP2 from the previous RQ values at 7 days, approximately 4 times as high
as control cells, but increased over 5 times in expression between 7 and 13 days. For the
13 day harvest, the highest RQ value was recorded by FBS, coming in at 10 times higher
than control cells. Laminin was found to have heightened expression of MMP2 about 4.4
fold that of control cells; there was no 13 day recording for fibronectin.
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Ratio of Twist/MMP2 expression
We initially predicted that MMP2 expression correlated with increased gene
expression of Twist; this hypothesis was confirmed in our experiment. When HF2587
cells were grown on the substrates fibronectin, laminin, vitronectin, collagen IV or FBS,
heightened MMP2 gene expression correlated with increased expression of Twist.
Interestingly, the ratio of MMP2 expression to Twist expression for the cells that formed
monolayers on FBS, vitronectin, fibronectin and laminin was in favor of MMP2. As for
collagen IV, Twist expression was greater than MMP2 at both 7 and 13 days (Fig. 16).
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Fibronectin
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Vitronectin
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0.542
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.487
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1
1.60
1.35
0.36
.39
.28

Figure 12. HF2587 cell Twist gene expression following 7 day harvest – A.) Graphical depiction of RQ
values from 7 day cell harvest. Error bars represent maximum and minimum values. B.) Table of exact RQ,
maximum and minimum values. RQ values where calculated using the comparative Ct method. ¨¨Ct =
¨Ct sample - ¨Ct reference ¨Ct = Ct gene of interest – Ct endogenous control. UBC was used as an
endogenous control and our values where normalized to the 7 day HF2587 cells grown in NMGF.
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B.
Sample
Neurosphere Media
Fetal Bovine Serum
Collagen IV
Fibronectin
Laminin
Vitronectin
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Figure 13. HF2587 cell Twist gene expression following 13 day harvest – A.) Graphical depiction
of RQ values from 13 day cell harvest. Error bars represent maximum and minimum values. B.)
Table of exact RQ, maximum and minimum values. RQ values where calculated using the
comparative Ct method. ¨¨Ct = ¨Ct sample - ¨Ct reference ¨Ct = Ct gene of interest – Ct
endogenous control. UBC was used as an endogenous control and our values where normalized to
the 13 day HF2587 cells grown in NMGF.
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B

Sample
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Collagen IV
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1
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1
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0.715
1.867
0.831

Minimum
1
.0554
1.561
0.562
0.761
0.738

Figure 14. HF2587 cell MMP2 gene expression following 7 day harvest – A.) Graphical depiction
of MMP2 RQ values from 7 day cell harvest. Error bars represent maximum and minimum values.
B.) Table of exact RQ, maximum and minimum values. RQ values where calculated using the
comparative Ct method. ¨¨Ct = ¨Ct sample - ¨Ct reference ¨Ct = Ct gene of interest – Ct
endogenous control. UBC was used as an endogenous control and our values where normalized to
the 7 day HF2587 cells grown in NMGF.
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Figure 15. HF2587 cell MMP2 gene expression following 13 day harvest – A.) Graphical
depiction of MMP2 RQ values from 13 day cell harvest. Error bars represent maximum and
minimum values. B.) Table of exact RQ, maximum and minimum values. RQ values where
calculated using the comparative Ct method. ¨¨Ct = ¨Ct sample - ¨Ct reference ¨Ct = Ct gene of
interest – Ct endogenous control. UBC was used as an endogenous control and our values where
normalized to the 13 day HF2587 cells grown in NMGF.
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Figure 16. Ratio of Twist/MMP2 gene expression following 7 and 13 days – A.) Side by side
comparison of Twist and MMP2 expression following 7 day harvest. It appears as though MMP2
expression is dependent of Twist expression. B.) Coexpression at 13 day harvest, once again is
appears as though MMP2 expression is dependent of Twist expression, but it’s interesting to note
that MMP2 is increased the most in cells that formed monolayers, linking it to migration as other
researchers have.
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V. Discussion
In this study the effects of neural ECM proteins on GBM invasive properties were
investigated by observing growth morphology and by measuring Twist1 and MMP2 gene
expression to reflect an EMT-like transition. We predicted that monolayer formation
caused by ECM protein plate coating would increase Twist expression and MMP2
expression would also increase as a downstream response to Twist. Our results,
however, suggest that while several ECM proteins induce monolayer formation, this
growth property is not uniformly linked to Twist1 expression as seen with whole serum
induction. Similarly, increases in Twist1 expression do not appear to directly induce
MMP2 expression, since some ECM proteins were able to induce MMP2 expression in
the absence of Twist1.
It has been previously reported that GBM undergoes an EMT-like transition,
although this EMT-like response does not involve the canonical cadherin switch and is
triggered but a sole transcription factor Twist 16,17. Our In vitro cell culturing system
mimics the findings of these earlier reports in that we have found TWIST to be upregulated in the presence of serum, and heightened Twist expression is associated with an
increase in MMP2 expression. Our results from day 7 to day 13 show significant
increases in both EMT markers Twist and MMP2 which verifies our cell culture system
as an accurate means of modeling glioma invasion. It has been widely accepted that
environmental factors of the neurological ECM have considerable influence on the ability
of glioma cells to migrate and invade18,36,39,41,52,53. However, the role of these proteins in
EMT glioma invasion has yet to be elucidated.
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We have made headway into this task by examining, the ability of the fibrous
proteins vitronectin, fibronectin, laminin and collagen IV in the initiation of EMT
through the upregulation of Twist and MMP2. Our findings provide new insight into the
formation of monolayers due to these ECM ligands and the connection of monolayer
formation with Twist induction. Our results confirmed that the fibrous ECM proteins
fibronectin, laminin and vitronectin formed monolayers to various degrees.
Comparatively, these monolayers where not similar in morphology, which shows that
cell-ECM binding occurs, are different affinities. This is in correspondence to others who
determined that monolayer formation of various ECM substrates is cell line specific32,53.
HF2587 cells grown on fibronectin, laminin, and vitronectin coated plates had
altered monolayer phenotypes. When these cells were grown on fibronectin the
monolayers exemplified slight cell-cell adherence and loose binding to the substrate. This
same finding has been seen with the GBM cell lines U-251 and SF-767, which show no
specific attachment to fibronectin at normal concentrations but slight attachment at higher
dose concentrations53. While harvesting the seeded HF2587 cells from these coated plates
the attachment was so loose that, pipetting the media back and forth lifted the cells form
the bottom of the wells diminishing the need to use trypsin. On the contrary, HF2587
cells grown on laminin coated wells showed pronounced adherence, within the first four
hours of seeding and continued to do so throughout the experiment. Laminin coated
plates reached 90% confluence within the first 72 hours of seeding, and cell counts from
the first harvest revealed that cell proliferation was unaffected by monolayer formation.
In fact, cell counts from the 7 day harvest, confirmed that cells grown on laminin coated
wells had the highest proliferation rate amongst the ECM proteins. Since no proliferation
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assay was undertaken, these results are more qualitative then quantitative. Results from
other studies have confirmed that laminin is the optimal adhesion substrate for GBM
cells, but there is conflicting evidence in regard to proliferation rates52,53.
The extracellular matrix protein vitronectin has been extensively studied and our
observations include increased cell-substrate adherence and formation of monolayers as
observed by others52,53. Like laminin, our cell counts during cell harvesting indicated
higher than expected proliferation rates. Our most intriguing ECM protein was collagen
IV, when cells where grown on collagen IV, monolayers did not form, while intact
spherical clusters of cells gathered to form massive cellular sheets. Cell counts from
collagen IV coated wells were substantially lower than all other ECM coated wells. This
finding is unlike others who have demonstrated the ability of collagen IV to form
monolayers and increase migration 52,53.
To determine the effectiveness of ECM proteins on the induction of EMT in
GBM, gene expression analysis for Twist and MMP2 was performed to conclude if ECM
proteins elicit expressional changes. This led us to several significant discoveries, the first
being that monolayer formation on vitronectin, laminin, and fibronectin had little to no
effect on the transcriptional activity of Twist. Comparatively, these same proteins
showed little effect on MMP2 expression at day 7 but, by day 13 the expression level of
MMP2 was significantly altered showing that there is a direct correlation to monolayer
formation and MMP2 expression. More importantly this time course also proves that
transcriptional up-regulation is a time dependent event. Twist expression was not
significantly altered from day 7 to 13, which opens up to discussion whether MMP2 is a
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direct downstream marker of Twist. Our most compelling evidence in the ECMs ability
to trigger Twist expression comes from the protein collagen IV.
Unlike, the proteins that elicited monolayer formation of HF2587 cells, cells
grown on collagen IV remained in spherical clusters and exhibited high Twist expression
and low MMP2 expression. In fact, MMP2 expression was much greater in vitronectin
and laminin when compared to collagen IV. This finding that collagen IV causes GBM
CSCs to sphere and up-regulate Twist is an exception to the findings done by others who
have demonstrated that Twists up-regulation is associated with increased migration and
cell-substrate binding rather than cell-cell adherance16,17.
These findings suggest that monolayer cellular adherence does not necessarily
mean an EMT-like conversion and the data presented here supports this idea. In an
attempt to make a logical explanation of the findings of this experiment, the possible role
of collagen IV could be to up-regulate Twist in GBM. Cells grown on collagen IV were
EMT-like in their slow growth rates and their induction of Twist, but did not show the
change in phenotypes from an epithelial-like state to a mesenchymal state. During the
progression of GBM EMT, the enlarging tumor mass comes into close contact with the
vasculature of the brain. This vasculature contains high concentrations of collagen IV and
laminin. When tumor cells associate with collagen IV this could initiate the up-regulation
of Twist,1 while laminin acts as a permissive substrate for migration. The fact that MMP2
was entirely up- regulated in monolayers further shows its role in aiding in invasiveness.
We can conclude that the monolayers formed on laminin, vitronectin and
fibronectin were not EMT –like due to high amounts of proliferation and low
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transcription of Twist. On the contrary, collagen IV was similar to an EMT-like
phenomenon in that proliferation slowed and transcription of Twist1 was heightened. But
further experiments must be carried out to clarify these results.
Areas of improvement for this study would include the use of a migration assay to
determine the effects of these proteins on cellular migration. Along with this a cell-titer
glow experiment should be done in order to determine the proliferation rates of HF2587
cells on the various ECM proteins. Equally important it would be interesting to find out if
other GBM cell lines exhibit similar Twist induction on collagen IV.
To conclude, our preliminary experiments show that collagen IV induces Twist
expression in the presence of serum free media which is a novel finding in the realm of
current GBM research. To confirm these preliminary results this experiment should be
carried out once again to confirm this, and it is now more than evident that our in vitro
culturing system is an accurate means to further conduct this research.
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